Skin manifestations of drug allergy

British Journal of Clinical Pharmacology

Volumn 71, Issue 5, 2011, Pages 672-683

  Ardern Jones, Michael R ^a   Friedmann, Peter S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Adverse drug reaction; Drug allergy; Skin; Toxic epidermal necrolysis

Indexed keywords

ABACAVIR; ACETYLCYSTEINE; ACETYLSALICYLIC ACID; ALLOPURINOL; ANTICONVULSIVE AGENT; CAPTOPRIL; CARBAMAZEPINE; CEPHALOSPORIN DERIVATIVE; CONTRAST MEDIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; INFLIXIMAB; INSULIN; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PENICILLIN DERIVATIVE; PREDNISOLONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ANTIBODY; ZINC;

ARTICLE; BLISTER; CLINICAL FEATURE; DRESS SYNDROME; DRUG DISPOSITION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; SINGLE DRUG DOSE; SKIN; SKIN ALLERGY; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE; TOXIC EPIDERMAL NECROLYSIS; UNSPECIFIED SIDE EFFECT; URTICARIA;

DRUG ERUPTIONS; EPIDERMAL NECROLYSIS, TOXIC; EXANTHEMA; HUMANS; T-LYMPHOCYTES;

EID: 79953839788     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03703.x     Document Type: Article

References (62)

1. Bigby M, Jick S, Jick H, Arndt K. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15, 438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358-63.
2. Hunziker T, Kunzi UP, Braunschweig S, Zehnder D, Hoigne R. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388-93.
3. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149: 1018-22.
4. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-95.
5. Merk HF, Hertl M. Immunologic mechanisms of cutaneous drug reactions. Semin Cutan Med Surg 1996; 15: 228-35.
6. Kenna JG, Satoh H, Christ DD, Pohl LR. Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J Pharmacol Exp Ther 1988; 245: 1103-9.
7. Martin JL, Kenna JG, Pohl LR. Antibody assays for the detection of patients sensitized to halothane. Anesth Analg 1990; 70: 154-9.
8. Leeder JS, Gaedigk A, Lu X, Cook VA. Epitope mapping studies with human anti-cytochrome P450 3A antibodies. Mol Pharmacol 1996; 49: 234-43.
9. Mauri-Hellweg D, Bettens F, Mauri D, Brander C, Hunziker T, Pichler WJ. Activation of drug-specific CD4+ and CD8+ T cells in individuals allergic to sulfonamides, phenytoin, and carbamazepine. J Immunol 1995; 155: 462-72.
10. Naisbitt DJ, Britschgi M, Wong G, Farrell J, Depta JP, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones. Mol Pharmacol 2003; 63: 732-41.
11. Coulter EM, Jenkinson C, Wu Y, Farrell J, Foster B, Smith A, McGuire C, Pease C, Basketter D, King C, Friedmann PS, Pirmohamed M, Park BK, Naisbitt DJ. Activation of T-cells from allergic patients and volunteers by p-phenylenediamine and Bandrowski's base. J Invest Dermatol 2008; 128: 897-905.
12. Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, Berry N, Stachulski AV, Clarke SE, Pichler WJ, Pirmohamed M, Park BK, Naisbitt DJ. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006; 118: 233-41.
13. Naisbitt DJ, Farrell J, Wong G, Depta JP, Dodd CC, Hopkins JE, Gibney CA, Chadwick DW, Pichler WJ, Pirmohamed M, Park BK. Characterization of drug-specific T cells in lamotrigine hypersensitivity. J Allergy Clin Immunol 2003; 111: 1393-403.
14. Davis MM, Bjorkman PJ. T-cell antigen receptor genes and T-cell recognition. Nature 1988; 334: 395-402.
15. Arstila TP, Casrouge A, Baron V, Even J, Kanellopoulos J, Kourilsky P. A direct estimate of the human alphabeta T cell receptor diversity. Science 1999; 286: 958-61.
16. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
17. Devary Y, Gottlieb RA, Lau LF, Karin M. Rapid and preferential activation of the c-jun gene during the mammalian UV response. Mol Cell Biol 1991; 11: 2804-11.
18. Schreck R, Baeuerle PA. A role for oxygen radicals as second messengers. Trends Cell Biol 1991; 1: 39-42.
19. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10: 2247-58.
20. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, Bannai S, Yamamoto M. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 2000; 275: 16023-9.
21. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 2009; 284: 13291-5.
22. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
23. Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134-9.
24. Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 2004; 428: 486.
25. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180-5.
26. Coombs RRA, Gell PGH. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Clinical Aspects of Immunology, eds Gell PGH, Coombs RRA. Oxford: Oxford University Press, 1968; 576-96.
27. Pichler WJ. Drug hypersensitivity reactions: classification and relationship to T-cell activation. In: Drug Hypersensitivity, 1st edn, ed. Pichler WJ. Basel: Karger, 2007; 168-89.
28. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357: 580-7.
29. Friedmann PS, Pickard C, Ardern-Jones MR, Bircher AJ. Drug-induced exanthemata: a source of clinical and intellectual confusion. European Journal Dermatology 2010; 20: 255-9.
30. Hernandez-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006; 37: 899-902.
31. Seishima M, Yamanaka S, Fujisawa T, Tohyama M, Hashimoto K. Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome. Br J Dermatol 2006; 155: 344-9.
32. Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006; 55: 1-8.
33. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-24.
34. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
35. Chave TA, Mortimer NJ, Sladden MJ, Hall AP, Hutchinson PE. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br J Dermatol 2005; 153: 241-53.
36. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
37. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998; 102: 1018-22.
38. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study. J Am Acad Dermatol 2008; 58: 33-40.
39. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis. Clinical and pathophysiologic aspects. J Am Acad Dermatol 1991; 25: 778-86.
40. Trautmann A, Klein CE, Kampgen E, Brocker EB. Severe bullous drug reactions treated successfully with cyclophosphamide. Br J Dermatol 1998; 139: 1127-8.
41. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000;48: 473-8.
42. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE. Inhibition of toxic epidermal necrolysis by blockade of cd95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
43. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006; 55: 9-16.
44. Prins C, Vittorio C, Padilla RS, Hunziker T, Itin P, Förster J, Bröcker EB, Saurat JH, French LE. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 2003; 207: 96-9.
45. Paquet P, Pierard GE. Soluble fractions of tumor necrosis factor-alpha, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with second-degree burns. Int J Mol Med 1998; 1: 459-62.
46. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-80.
47. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-9.
48. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146: 707-9.
49. Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005; 116: 923-4.
50. Wojtkiewicz A, Wysocki M, Fortuna J, Chrupek M, Matczuk M, Koltan A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol 2008; 88: 420-1.
51. Gubinelli E, Canzona F, Tonanzi T, Raskovic D, Didona B. Toxic epidermal necrolysis successfully treated with etanercept. J Dermatol 2009; 36: 150-3.
52. Di Lernia V, Grenzi L, Guareschi E, Ricci C. Rapid clearing of acute generalized exanthematous pustulosis after administration of ciclosporin. Clin Exp Dermatol 2009; 34: 757-9.
53. Gencoglan G, Tosun M, Aktepe F. The molecular mechanism of etanercept, an anti-tumour necrosis factor-alpha receptor-fusion protein, in the treatment of acute generalized exanthematous pustulosis. J Dermatolog Treat 2009; 20: 241-5.
54. Descamps V, Bouscarat F, Laglenne S, Aslangul E, Veber B, Descamps D, Saraux JL, Grange MJ, Grossin M, Navratil E, Crickx B, Belaich S. Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome. Br J Dermatol 1997; 137: 605-8.
55. Suzuki Y, Inagi R, Aono T, Yamanishi K, Shiohara T. Human herpesvirus 6 infection as a risk factor for the development of severe drug-induced hypersensitivity syndrome. Arch Dermatol 1998; 134: 1108-12.
56. Tohyama M, Yahata Y, Yasukawa M, Inagi R, Urano Y, Yamanishi K, Hashimoto K. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch Dermatol 1998; 134: 1113-7.
57. Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol 2010; May 18 [Epub ahead of print].
58. Barbaud A. Drug patch testing in systemic cutaneous drug allergy. Toxicology 2005; 209: 209-16.
59. Nyfeler B, Pichler WJ. The lymphocyte transformation test for the diagnosis of drug allergy: sensitivity and specificity. Clin Exp Allergy 1997; 27: 175-81.
60. Kano Y, Hirahara K, Mitsuyama Y, Takahashi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62: 1439-44.
61. Frew A. General principles of investigating and managing drug allergy. Br J Clin Pharmacol 2011; 71: 642-6.
62. Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol 2010; 10: 291-6.